A multiple antigen peptide is a branched construct built around a lysine or another defined core. MAP4 and MAP8 are not concentration grades; they describe nominal valency. When qualifying a multiple antigen peptide MAP synthesis supplier, ask how the laboratory verifies branch completeness and distinguishes the target from partially substituted cores.
Select architecture before requesting purity
Define core structure, number of branches, epitope sequence, spacer, termini and any focal functional group. Longer or hydrophobic epitopes may be more practical as MAP4 than MAP8 because higher branch density can worsen aggregation and synthesis access.
Multi-epitope MAP designs require explicit branch assignment. A generic statement that all epitopes are present does not establish their position or stoichiometry.
Incomplete branches are characteristic impurities
Each coupling must proceed across several arms. One failed branch creates a product close in size and chemistry to the intended construct. Crowding increases as the arms grow. Lower resin loading, extended coupling or tailored spacers may help, but the crude profile should be reviewed.
Purification and analysis are difficult
Branched MAPs can show broad reversed-phase peaks, limited solubility and complex mass spectra. Conventional area normalization may overstate certainty when partially branched species overlap. High-resolution MS, targeted deconvolution and amino-acid analysis can provide complementary evidence.
For high-valency material, the supplier should state analytical limitations honestly. A single sharp peak is not the only sign of quality, and a broad peak is not automatically failure.
Content basis must match the experiment
Gross MAP weight includes counterion, water and residual salts. Define whether the delivered amount refers to complete construct mass, peptide-arm equivalent or net peptide content. This distinction affects comparison with a linear peptide or carrier conjugate.
MAP and carrier conjugate are different materials
A MAP presents defined branches on a synthetic core. A KLH conjugate contains a heterogeneous protein carrier and variable peptide loading. The choice depends on the research design, not a claim that one is universally superior. If comparing formats, keep the linear epitope sequence and spacer documented.
Packaging should reflect aggregation risk
Request small aliquots, low-bind containers and a tested reconstitution approach. Avoid repeated freeze-thaw in concentrated solution. A clear vial does not prove every branch remains molecularly dispersed.
- MAP2, MAP4 or MAP8 core definition.
- Epitope, spacer and terminal configuration.
- Crude conversion and branch-completeness evidence.
- HPLC/MS methods with stated limitations.
- Content basis, counterion and solubility data.
Should a buyer choose MAP4 or MAP8? Epitope length, hydrophobicity, required density and analytical tractability all matter. Provide the sequence, intended format, amount and downstream assay. The supplier should discuss incomplete branching and purification risk before promising a high-purity number.